The projects include efficacy, safety and tolerance studies for new biomedical components, stem cell implants, dental implants, kidney transplants and the validation of latest-generation surgical robots like Bitrack, among others.
Specipig CEO Jaume Amat and Business Development Manager Assela Bosch.
Company is positioned as a reference preclinical CRO for the development of new drugs, advanced therapies and medical technology.
With 50% growth in turnover.
99% of the company’s revenue is international.
Barcelona (Spain), 15 March 2022 – Specipig closed 2021 achieving 150 preclinical research projects and reinforcing its position as the reference Contract Research Organization (CRO) for the global pharmaceutical, biotechnology and medical technology industry.
The projects include efficacy, safety and tolerance studies for new biomedical components, stem cell implants, dental implants, kidney transplants and the validation of latest-generation surgical robots like Bitrack, among others.
Jaume Amat, CEO of Specipig, notes that the company ended the year positively for the third time in a row since it started in 2013, increasing 50% from last year: “We believe these results are very positive because they show a consolidation of Specipig’s growth in line with our goals and they mean we can continue investing in cutting-edge facilities and talent.” 99% of the company’s revenue is international, with clients in more than 10 countries.
In 2022, Specipig will continue boosting its local and international presence. “Despite being a small CRO, our experience and specialisation are unique and highly valued in the industry, as are our agility, flexibility and open doors for our customers,” explains Specipig Business Development Manager Assela Bosch.
Specipig has facilities near Barcelona airport, a strategic location to collaborate with international experts, and a team of 20 qualified professionals (20% hold a PhD and 55% graduate degrees).
In terms of animal-welfare and quality accreditations, the company has Good Laboratory Practices (GLP) certification and meets the guidelines issued by the European Medicines Agency (EMA), the US Food and Drug Agency (FDA), ISO 10993 and other relevant healthcare authorities. In the coming months, the company expects to receive ISO 13485 certification for medical devices and the accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
About Specipig
Specipig is a preclinical Contract Research Organization (CRO) that works with industry, hospitals and research centres to accelerate development of new drugs, advanced therapies and medical devices. Created in 2013 and based in the Barcelona area, Specipig is pioneer in offering comprehensive preclinical services at its R&D centre. Specipig is developing its own genetic line of miniature pigs in collaboration with Semen Cardona and geneticists at the IRTA (Government of Catalonia).
More information: www.specipig.com
Media contact:
Gemma Escarré Comms
M +34 667 76 15 24
specipig@gemmaescarre.com
www.specipig.com